UroGen Pharma (URGN) Tops Q2 EPS by 2c

UroGen Pharma (NASDAQ: URGN) reported Q2 EPS of ($0.28), $0.02 better than the analyst estimate of ($0.30). Revenue for the quarter came in at $72.5 million versus the consensus estimate of $62.16 million.

For earnings history and earnings-related data on UroGen Pharma (URGN) click here.

You May Also Be Interested In

• Pizza Hut CEO Aaron Powell resigns
• Credo Technology Group Holding (CRDO) Tops Q1 EPS by 4c; offers guidance
• NVIDIA (NVDA) Said To Near $14 bln Deal For Hugging Face This Week - Bloomberg